Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): Results from ARIES observational cohort study (OCS) and confirmation of BRITE data on BV beyond progression (BBP)

被引：1
|
作者：
Cohn, A. L.
Bekaii-Saab, T.
Bendell, J. C.
Hurwitz, H.
Kozloff, M.
Roach, N.
Tezcan, H.
Feng, S.
Sing, A.
Grothey, A.
机构：
[1] Rocky Mt Canc Ctr, Denver, CO USA
[2] Ohio State Univ, Columbus, OH 43210 USA
[3] Sarah Cannon Res Inst, Nashville, TN USA
[4] Duke Univ, Med Ctr, Durham, NC USA
[5] Ingalls Hosp, Harvey, IL USA
[6] Univ Chicago, Harvey, IL USA
[7] C3, Alexandria, VA USA
[8] North Idaho Canc Ctr, Coeur Dalene, ID USA
[9] Genentech Inc, San Francisco, CA 94080 USA
[10] Mayo Clin, Coll Med, Rochester, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.3596
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3596
引用
收藏
页数：1
相关论文
共 50 条
  • [31] CLINICAL OUTCOMES FOR NON-SMALL CELL LUNG CANCER (NSCLC) FROM THE ARIES STUDY: A BEVACIZUMAB (BV) TREATMENT OBSERVATIONAL COHORT STUDY (OCS)
    Lynch, T.
    Jahanzeb, M.
    Kosty, M.
    Robles, R.
    Wozniak, A.
    Teng, S. L.
    Wang, L.
    Navarro, W. H.
    ANNALS OF ONCOLOGY, 2008, 19 : 93 - 93
  • [32] Clinical Outcomes in Elderly Patients with Metastatic Colorectal Cancer Receiving Bevacizumab and Chemotherapy: Results from the BRiTE Observational Cohort Study
    Kozloff, Mark F.
    Berlin, Jordan
    Flynn, Patrick J.
    Kabbinavar, Fairooz
    Ashby, Mark
    Dong, Wei
    Sing, Amy P.
    Grothey, Axel
    ONCOLOGY, 2010, 78 (5-6) : 329 - 339
  • [33] Management of hypertension (HTN) in patients (pts) with metastatic colorectal cancer (MCRC) treated with bevacizumab (BV) plus chemotherapy (CT)
    Kozloff, M.
    Hainsworth, J.
    Badarinath, S.
    Cohn, A.
    Flynn, P.
    Dong, W.
    Suzuki, S.
    Purdie, D.
    Yi, J.
    Sugrue, M.
    Grothey, A.
    ANNALS OF ONCOLOGY, 2007, 18 : VII80 - VII80
  • [34] Management of hypertension (HTN) in patients (pts) with metastatic colorectal cancer (mCRC) treated with bevacizumab (BV) plus chemotherapy (CT)
    Kozloff, M.
    Hainsworth, J.
    Badarinath, S.
    Cohn, A.
    Flynn, P.
    Dong, W.
    Purdie, D.
    Yi, J.
    Sugrue, M.
    Grothey, A.
    EJC SUPPLEMENTS, 2007, 5 (04): : 250 - 251
  • [35] Impact of first-line bevacizumab (BV) on the clinical outcomes of patients with metastatic colorectal cancer (mCRC) treated with second-line FOLFIRI plus BV
    Muro, Kei
    Yamanaka, Takeharu
    Suenaga, Mitsukuni
    Nishina, Tomohiro
    Yasul, Hisateru
    Ura, Takashi
    Denda, Tadamichi
    Ikeda, Junichi
    Esakl, Taito
    Nishisaki, Hogara
    Takano, Yoshinao
    Kondo, Ken
    Takeda, Koji
    Takahashi, Yasuo
    Endo, Kazuya
    Sugiyama, Yasuyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [36] BEVACIZUMAB PLUS CHEMOTHERAPY IN 2ND LINE METASTATIC COLORECTAL CANCER (MCRC): INITIAL RESULTS FROM ARIES, A SECOND BEVACIZUMAB OBSERVATIONAL COHORT STUDY (OCS)
    Bekaii-Saab, T.
    Bendell, J.
    Cohn, A.
    Hurwitz, H.
    Kozloff, M.
    Roach, N.
    Tezcan, H.
    Feng, S.
    Sing, A.
    Grothey, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 20 - 20
  • [37] Phase Ib study of dulanermin combined with FOLFIRI (with or without bevacizumab [BV]) in previously treated patients (Pts) with metastatic colorectal cancer (mCRC)
    Kasubhai, Saifuddin M.
    Bendell, Johanna C.
    Kozloff, Mark
    Kapp, Amy V.
    Ashkenazi, Avi
    Royer-Joo, Stephanie
    Portera, Chia C.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [38] Initial results from aries, a multi-indication bevacizumab observational cohort study (OCS). Characteristics of metastatic colorectal cancer patients receiving BV and chemotherapy (CT) in 2nd line
    Bekaii-Saab, T.
    Grothey, A.
    Bendell, J.
    Cohn, A.
    Kozloff, M.
    Roach, N.
    Sargent, D.
    Tezcan, H.
    Purdie, D.
    Sugrue, M.
    ANNALS OF ONCOLOGY, 2008, 19 : 17 - 17
  • [39] Clinical benefit from bevacizumab (BV) in responding (R) and non-responding (NR) patients (pts) with metastatic colorectal cancer (mCRC).
    Mass, RD
    Sarkar, S
    Holden, SN
    Hurwitz, H
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 249S - 249S
  • [40] Safety of bevacizumab (BV) combined with chemotherapy (CTX) in patients (pts) with non-small cell lung cancer (NSCLC): interim results from the ARIES Lung observational cohort study (OCS)
    Jahanzeb, M.
    Fischbach, N.
    Kosty, M.
    Kumar, P.
    Spigel, D.
    Wozniak, A.
    Teng, S. L.
    Wang, L.
    Sing, A.
    Lynch, T.
    EJC SUPPLEMENTS, 2009, 7 (02): : 507 - 507
12345